Effect of Lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice

Abstract

We investigated the probiotic properties of Lactobacillus acidophilus NS1, such as acid resistance, bile tolerance, adherence to HT-29 cells, and cholesterol assimilation activity. In an animal study, 7-wk-old male C57BL/6 mice were fed a normal diet, a high-fat diet (HFD), or an HFD with L. acidophilus NS1 (ca. 1.0×10(8) cfu/mL) for 10 wk. Total cholesterol and low-density lipoprotein (LDL) cholesterol levels were significantly lower in mice fed an HFD with L. acidophilus NS1 than in those fed an HFD only, whereas high-density lipoprotein cholesterol levels were similar between these 2 groups. To understand the mechanism of the cholesterol-lowering effect of L. acidophilus NS1 on the HFD-mediated increase in plasma cholesterol levels, we determined mRNA levels of genes involved in cholesterol homeostasis in the liver. Expression of sterol regulatory element-binding protein 2 (Srebp2) and LDL receptor (Ldlr) in the liver was dramatically reduced in mice fed a HFD compared with those fed a normal diet. When L. acidophilus NS1 was administered orally to HFD-fed mice, an HFD-induced suppression of Srebp2 and Ldlr expression in the liver was abolished. These results suggest that the oral administration of L. acidophilus NS1 to mice fed an HFD increased the expression of Srebp2 and Ldlr in the liver, which was inhibited by high fat intake, thus leading to a decrease in plasma cholesterol levels. Lactobacillus acidophilus NS1 could be a useful probiotic microorganism for cholesterol-lowering dairy products and the improvement of hyperlipidemia and hepatic lipid metabolism.

The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice

“…Likewise, it was not possible to assess the impact of other potential probiotic cholesterol-lowering mechanisms such as the conversion of cholesterol to coprostanol, short chain fatty acid production 55 and the assimilation of bile acids 56, 57 . Probiotics have also been shown to reduce blood TG levels 37, 38 or impart anti-inflammatory effects 34, 40 in HFD fed C57BL/6J mice but these responses were not seen in our study (Table 1) possibly as a result of the short intervention period.…”

Dietary fucoidan modulates the gut microbiota in mice by increasing the abundance ofLactobacillusandRuminococcaceae

“…Lactobacillus acidophilus 45 , Lactobacillus gasseri 46 , Lactobacillus curvatus and Lactobacillus plantarum 47 have all been successfully used as effective disease modifiers for obesity, we tentatively put forward that fucoidan may have gut microbiota as its primary drug target during the treatment of obesity. Interestingly, a recent study partly echoed our hypothesis by demonstrating that fucoidan from Fucus evanescens (FuF) can enrich the biomass of B. longum and B. bifidum both in vivo and in vitro 18 .…”

In vitro characterisation of probiotic properties of Enterococcus faecium and Enterococcus durans strains isolated from raw milk and traditional dairy products

“…Active uptake of bacteria can lead to a decrease in serum cholesterol levels by inhibiting the enterohepatic circulation of bile salts and providing deconjugation of bile salts. Therefore, free bile acids are less soluble than the conjugated bile salts and are less absorbed from the intestinal tract (Corzo and Gilliland ; Pereira et al ; Song et al ). Rossi et al () found that cholesterol‐lowering abilities of E. faecium and different lactic acid bacteria varied depending on the species, and some cultures lowered the cholesterol at higher rates.…”